ClinicalTrials.gg
Not yet recruitingNCT07914023Updated Nov 3, 2026

Art and Mindfulness in Fibromyalgia Rehabilitation at the University Museum

An interventional study of Museum-Based Mindfulness & Body Awareness Program and Gym-Based Mindfulness & Body Awareness Program in Fibromyalgia, sponsored by G. d'Annunzio University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by G. d'Annunzio University · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This randomized controlled trial investigates the efficacy of a mindfulness-based rehabilitation program delivered in a non-traditional environment rich in art and beauty (the University Museum, UD'A) compared to a traditional university gym setting (CARES) for patients with fibromyalgia.

The main question the study aims to answer is whether conducting mindfulness sessions in a museum setting can better reduce muscle pain (primary objective) and improve body awareness and quality of life (secondary objectives) compared to a standard gym setting. Additionally, the study evaluates autonomic nervous system responses using non-invasive thermal infrared imaging.

Furthermore, this protocol incorporates an exploratory home-based maintenance component-utilizing an illustrated educational brochure and a preregistered video of previously learned exercises-during a four-week follow-up period (T1-T2) to assess adherence, feasibility, and the maintenance of therapeutic benefits

02

Conditions studied

  • Fibromyalgia

Browse trials for

03

In context

Fibromyalgia

1,375 studies on the registry are indexed under Fibromyalgia; 275 are open to participants now.

This study's planned enrollment of 44 is below the median of 60 across 1,060 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

G. d'Annunzio University is the lead sponsor of 66 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written informed consent provided prior to study initiation.
  • Confirmed diagnosis of Fibromyalgia Syndrome according to the ACR (American College of Rheumatology) criteria.
  • Age between 18 and 60 years.
  • Stable pharmacological treatment for fibromyalgia for at least 4 weeks prior to enrollment, with agreement not to modify dosage during the study unless strictly necessary.
  • Ability to comprehend, speak, and read Italian to complete self-reported outcome measures and participate in group sessions.
  • Ability to provide written consent and follow study procedures.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or active psychiatric disorders (e.g., severe clinical depression, psychosis, bipolar disorder) preventing participation in group sessions or self-report evaluations.
  • Severe cardiovascular, respiratory, metabolic, or systemic diseases that contraindicate low-to-moderate physical activity.
  • Concomitant autoimmune or inflammatory rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis).
  • Presence of severe neurological disorders (e.g., Parkinson's disease, multiple sclerosis, stroke sequelae).
  • Regular participation in structured mindfulness, yoga, or body awareness programs within the last 6 months.
  • Ongoing pregnancy or planned pregnancy during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Museum-Based Mindfulness Group

    Participants assigned to this arm receive an 8-week mindfulness and body awareness exercise program (2 sessions per week, 60 minutes each) conducted in a non-traditional setting rich in art and beauty (University Museum, UdA). This is followed by a 4-week home-based maintenance period using an illustrated educational brochure and guided exercise videos.

    Behavioral: Museum-Based Mindfulness & Body Awareness Program

  • Active comparator
    Gym-Based Mindfulness Group

    Participants assigned to this arm receive the exact same 8-week mindfulness and body awareness exercise program (2 sessions per week, 60 minutes each) delivered in a standard university gym setting (CARES center). This is followed by the same 4-week home-based maintenance period using an illustrated educational brochure and guided exercise videos.

    Behavioral: Gym-Based Mindfulness & Body Awareness Program

Interventions

  • BehavioralMuseum-Based Mindfulness & Body Awareness Program

    An 8-week structured group program (2 sessions/week, 60 minutes each) combining mindfulness techniques, body awareness practices, and gentle postural exercises, conducted inside the University Museum (UdA). Includes an additional 4-week home maintenance phase with educational brochures and instructional videos.

  • BehavioralGym-Based Mindfulness & Body Awareness Program

    An 8-week structured group program (2 sessions/week, 60 minutes each) combining mindfulness techniques, body awareness practices, and gentle postural exercises, conducted in a traditional university gym setting (CARES). Includes an additional 4-week home maintenance phase with educational brochures and instructional videos.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Pain Intensity on the Visual Analog Scale (VAS)

    Time frame: Baseline (T0), post-intervention at 8 weeks (T1), and follow-up at 12 weeks (T2)

  2. Change from Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score

    Total score of the Fibromyalgia Impact Questionnaire (FIQ) assessing overall fibromyalgia disease severity and functional impact across three domains: function, overall impact, and symptoms. Total score ranges from 0 to 100, where higher scores reflect greater symptom severity and impact on daily life.

    Time frame: Baseline (T0), Post-intervention at 8 weeks (T1), and Follow-up at 12 weeks (T2)

  3. Adherence to Home-Based Exercise Maintenance Program

    Adherence to the home-based maintenance program (guided by educational brochure and preregistered videos) measured as the percentage of completed prescribed exercise sessions recorded via a self-reported daily exercise log during the 4-week follow-up period. Adherence is calculated as (Number of completed sessions / Total prescribed sessions) \* 100.

    Time frame: Daily during the 4-week follow-up period (from Week 8 to Week 12)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 515 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 12 months is close to that.

Counting every sponsor, half of 527 studies reached it within 13 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07914023
Lead sponsor
G. d'Annunzio University
Responsible party
Teresa Paolucci (MD, PhD, Associate Professor, G. d'Annunzio University) — Principal investigator
First posted
Nov 3, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion